Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Withdrawn
Trial end date:
2019-08-15
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects of sirolimus and NY-ESO-1 protein with
MIS416 in treating patients stage II-IV ovarian, fallopian tube, or primary peritoneal
cancer. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Vaccine therapy, like Y-ESO-1 protein with MIS416, may strengthen the immune
system to find and kill tumor cells. Biological therapies, such as sirolimus, use substances
made from living organisms that may stimulate or suppress the immune system in different ways
and stop tumor cells from growing. Giving sirolimus and vaccine therapy may work betting in
treating patients with ovarian, fallopian tube or primary peritoneal cancer.